Latest Media Releases

All A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

Nyradas NYX-PCSK9i with Statin Achieves 65% Cholesterol Reduction in Preclinical Study (ASX:NYR)

Nyrada Inc (ASX: NYR) (“Nyrada” or “the Company”) a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurolo...read more

Nyrada - Improved Drug Candidate Selected for WRAIR Studies (ASX:NYR)

Nyrada Inc (ASX: NYR), a preclinical stage, drug development company specialising in novel small molecule drugs to treat cardiovascular and neurological diseases, today announces the selection of a ...read more

Nyrada Reports Half Year FY2021 Results (ASX:NYR)

To view the report, download the attached PDF.

Nyrada Reports Further Results from Cholesterol Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report new additional exploratory results of its in vivo cholesterol efficacy study, first announced on 21 December 2020. The study used a mouse model that has be...read more

57% Reduction in Total Cholesterol from Nyradas NYX-PCSK9i In Vivo Study (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging efficacy results from its cholesterol-lowering drug program which is directed at developing an oral PCSK9 inhibitor treatment for hypercholestero...read more

Nyrada Brain Injury Drug Pharmacokinetic Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) reports results from a preclinical pharmacokinetic study of its two lead Brain Injury drug candidates. Both candidates have achieved durable therapeutic levels when administere...read more

Nyrada Cholesterol-Lowering Drug Study Results (ASX:NYR)

Nyrada Inc (ASX: NYR) is pleased to report encouraging preclinical results from its cholesterol-lowering program to develop a drug to treat hypercholesterolemia. A study using healthy donor human...read more

Milestone Achieved in the Nyrada Brain Injury Program (ASX:NYR)

Nyrada Inc (ASX: NYR) provides an update on one of its leading programs for treatment of brain injury. Nyrada has shown in a preclinical pharmacokinetic study that its lead candidate compounds ca...read more

Update on Progress in Nyrada Programs (ASX:NYR)

Highlights: Two lead R&D programs progressing as planned and on-budget Brain injury program leads to discovery of a new generation of more potent drug candidates PCSK9 (cholesterol-lowerin...read more

Nyrada, Inc Corporate Presentation (ASX:NYR)

Nyrada listed on the Australian Securities Exchange on 16 January 2020 (ASX:NYR) with a vision to become a high-growth pharmaceutical company, specialising in drug discovery and early stage developm...read more

Nyrada (ASX:NYR) Commences Trading on the ASX (ASX:NYR)

Initial Public Offer fully subscribed with maximum A$8.5m raised Funds to be used to progress development of four first-in-class drugs addressing major global unmet needs: the high proportion of...read more

Listing of Nyrada Inc. spin-off on ASX (ASX:NYR)

Noxopharm (ASX: NOX) announced the listing on 17 Jan 2020 on the ASX (ASX:NYR) of its spin-off company, Nyrada Inc (Nyrada). The IPO Offer was fully subscribed, with A$8.5M being raised. ...read more

Viewing: 1 - 12 of 12 Previous | Next